View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 18, 2016

ViiV reports ARIA Phase IIIb trial shows superior efficacy for Triumeq to treat HIV

ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (TDF / FTC) in women with HIV.

ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (TDF / FTC) in women with HIV.

The open-label, international, multi-centre study enrolled 495 treatment-naïve adult women.

The data showed statistically superior viral suppression (HIV-1 RNA <50 c/mL) rates at week 48% to 82% versus 71%  respectively.

Non-inferiority, as well as superiority endpoints were met, with superiority being driven by lower rates of both virological failures and discontinuations due to adverse events (AEs) in the dolutegravir / abacavir / lamivudine group.

"We are committed to ensuring that the specific treatment needs of women are investigated."

The safety profile of dolutegravir / abacavir / lamivudine was found to be favourable compared to ATV/r plus TDF/FTC, as fewer drug-related AEs reported on the dolutegravir / abacavir / lamivudine arm (33% vs 49%). There were also fewer AEs leading to discontinuation compared to those in the ATV/r and TDF/FTC arm (4% vs 7%).

Drug-related AEs reported in the dolutegravir / abacavir / lamivudine arm included, nausea, diarrhoea,  headache, and dyspepsia .

In the ATV/r and TDF/FTC group, drug-related AEs included nausea, diarrhoea, ocular icterus, dyspepsia, headache, and jaundice.

Fewer subjects met virologic non-response criteria (VL >50c/mL) in the dolutegravir / abacavir / lamivudine arm (6%) compared to the other group (14%) at week 48.

Of the women that met protocol-defined virologic withdrawal criteria, none on the dolutegravir / abacavir / lamivudine arm had treatment-emergent resistance mutations to the components of dolutegravir / abacavir / lamivudine, compared with one in the comparator group.

ViiV Healthcare chief scientific and medical officer John Pottage said: "Women account for more than half of the almost 35 million adults living with HIV worldwide, yet unfortunately they are consistently under-represented in HIV clinical trials.

"For this reason, we are committed to ensuring that the specific treatment needs of women are investigated.

“This trial not only provides physicians with important additional information about Triumeq, it also builds on the strong body of evidence supporting the efficacy of dolutegravir-based regimens in a broad range of patient populations."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena